AbbVie scientists are committed to shaping the way cancer is treated by discovering and developing therapies that may help address the unmet needs of people affected by cancer around the world.
Abbvie scientists at work
Take a deep dive into AbbVie's research on chronic lymphocytic leukemia and multiple myeloma.
CLL Pathways and Target
Our scientists and researchers are committed to employing their vast knowledge of and expertise in various cancer pathways to discover world-class therapies.
Delivering a robust pipeline
Investigational drugs mentioned are for use in clinical studies only, and may be studied alone or in combination with drugs for indications that have not been approved by the FDA. Approved drugs mentioned are also being studied for uses for which they are not approved. Safety and efficacy have not been established for any of these drugs for the uses being studied.
AbbVie in no way intends to recommend or imply that these drugs should be used for unapproved uses.
With over 190 global clinical trials currently in development, AbbVie is committed to addressing today's unmet medical needs.
Connecting research and clinical practice
In order to address significant unmet medical needs, AbbVie aims to expedite the clinical development process for oncology treatments through the use of streamlined clinical trial designs that utilize biochemical markers, imaging technologies and definitive, profound clinical endpoints. Below is a select list of some of our active clinical trials.
Investigational drugs mentioned are for use in clinical studies only, and may be studied alone or in combination with drugs for indications that have not been approved by the FDA. Approved drugs mentioned are also being studied for uses for which they are not approved.
Safety and efficacy have not been established for any of these drugs for the uses being studied. AbbVie in no way intends to recommend or imply that these drugs should be used for
Based on the selected filters, there are no results matching your criteria. Please reduce the number of filters selected or clear all to broaden your search. You may also visit clinicaltrials.gov to request additional information.
A Phase 1 Study Evaluating the Safety and Pharmacokinetics of Venetoclax in Japanese Subjects With Hematological Malignancies
A Phase 1b/ 2 Study Evaluating the Safety and Efficacy of Obinutuzumab in Combination With Polatuzumab Vedotin and Venetoclax in Patients With Relapsed or Refractory Follicular (FL) or Diffuse Large B-Cell Lymphoma (DLBCL)
A Phase 1b Multicenter Dose-Finding and Safety Study Of Venetoclax and Obinutuzumab in Patients With Relapsed or Refractory or Previously Untreated Chronic Lymphocytic Leukemia (CLL)
A Phase 1b, Open-Label Study Evaluating the Safety and Pharmacokinetics of Venetoclax (GDC-0199, ABT-199) in Combination With Bendamustine+Rituximab (BR) or Bendamustine+Obinutuzumab (BG) in Patients With Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia (CLL)
A Phase 1b/2 Study of Obinutuzumab, Ibrutinib, and Venetoclax for Relapsed and Previously Untreated Chronic Lymphocytic Leukemia (CLL)
A Multi-institution Phase 1/1b Study of Ibrutinib With ABT-199 in Relapsed/Refractory Mantle Cell Lymphoma (MCL)
A Phase 1/2 Study of ABT-199 in Combination With Low-Dose Cytarabine in Treatment-Naïve Subjects With Acute Myelogenous Leukemia Who Are ≥ 65 Years of Age and Who Are Not Eligible for Standard Anthracycline-Based Induction Therapy
A Randomized, Placebo-Controlled, Double-Blind, Phase 3 Study Evaluating Safety and Efficacy of the Addition of Veliparib Plus Carboplatin Versus the Addition of Carboplatin to Standard Neoadjuvant Chemotherapy Versus Standard Neoadjuvant Chemotherapy in Subjects With Early Stage Triple Negative Breast Cancer (TNBC) (Brightness)
A Randomized, Double-Blind, Multicenter, Phase 3 Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Placebo Plus Carboplatin and Paclitaxel in Previously Untreated Advanced or Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC) (Vesta)
A Phase 3 Randomized, Placebo-Controlled Trial of Carboplatin and Paclitaxel With or Without the PARP Inhibitor Veliparib (ABT-888) in HER2-Negative Metastatic or Locally Advanced Unresectable BRCA-Associated Breast Cancer (Brocade3)
A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP Inhibitor) in Subjects With Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
A Randomized, Open-Label, Multicenter, Phase 3 Trial Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Investigator's Choice of Standard Chemotherapy in Subjects Receiving First Cytotoxic Chemotherapy for Metastatic or Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC) and Who Are Current or Former Smokers (Vela)
A Phase 1 Dose Escalation and Phase 2 Randomized, Placebo-Controlled Study of the Efficacy and Tolerability of Veliparib in Combination With Paclitaxel/Carboplatin-Based Chemoradiotherapy Followed by Veliparib and Paclitaxel/Carboplatin Consolidation in Subjects With Stage 3 Non-Small Cell Lung Cancer (NSCLC)
A Phase 1 Dose Escalation and Phase 2 Randomized Double-Blind Study of Veliparib in Combination With Carboplatin and Etoposide as a Therapy of Treatment-Naïve Extensive Stage Disease Small Cell Lung Cancer (SCLC)
A Phase 1 Study Evaluating the Safety and Pharmacokinetics of ABT-414 for Subjects With Glioblastoma Multiforme (GBM)
A Randomized, Placebo-Controlled Phase 2b/3 Study of ABT-414 With Concurrent Chemoradiation and Adjuvant Temozolomide in Subjects With Newly Diagnosed Glioblastoma (GBM) With Epidermal Growth Factor Receptor (EGFR) Amplification (INTELLANCE 1)
ABT-414 Alone or ABT-414 Plus Temozolomide vs. Lomustine or Temozolomide for Recurrent Glioblastoma (GBM): A Randomized Phase II Study of the EORTC Brain Tumor Group (EORTC Protocol 1410-BTG) (INTELLANCE 2)
A Phase 2 Study of the Combination of Elotuzumab With Lenalidomide as Maintenance Therapy Post Autologous Stem Cell Transplant in Patients With Multiple Myeloma (MM)
A Phase 1 Open-Label Dose Escalation and Randomized Cohort Expansion Study of the Safety and Tolerability of Elotuzumab (BMS-901608) Administered in Combination With Either Lirilumab (BMS-986015) or Urelumab (BMS-663513) in Subjects With Multiple Myeloma (MM)
A Phase 1 Study of Elotuzumab in Combination With Autologous Stem Cell Transplantation and Lenalidomide Maintenance for Multiple Myeloma (MM)
An Open-Label, Single-Arm, Phase 2a Study of Bortezomib, Lenalidomide,Dexamethasone and Elotuzumab in Newly Diagnosed Multiple Myeloma (MM)
A Phase 2 Trial of Combination of Elotuzumab and Lenalidomide +/- Dexamethasone in High-Risk Smoldering Multiple Myeloma (MM)
A Phase 2 Single-Arm Study of Elotuzumab in Combination With Pomalidomide and Low-Dose Dexamethasone (EPd) in Patients With Multiple Myeloma (MM) Relapsed or Refractory to Prior Treatment With Lenalidomide
A Randomized Phase 3 Trial on the Effect of Elotuzumab in VRD Induction /Consolidation and Lenalidomide Maintenance in Patients With Newly Diagnosed Myeloma
A Randomized Phase 1/2 Study of Optimal Induction Therapy of Bortezomib, Dexamethasone and Lenalidomide With or Without Elotuzumab (NSC-764479) for Newly Diagnosed High-Risk Multiple Myeloma (HRMM)
A Phase 1 Study of ABBV-221 in Subjects With Advanced Solid Tumor Types Likely to Exhibit Elevated Levels of Epidermal Growth Factor Receptor (EGFR)
A Phase 1 Study Evaluating the Safety and Pharmacokinetics of ABBV-075 in Subjects With Advanced Cancer
NOTE: Ibrutinib is developed by Pharmacyclics LLC, a wholly owned subsidiary of AbbVie. To see clinical trials related to ibrutinib, please visit Clincialtrials.gov.
A Study of Rovalpituzumab Tesirine (SC16LD6.5) in the Frontline Treatment of Patients With Delta-Like Protein 3-Expressing Extensive Stage Small Cell Lung Cancer
An Intensive QT/QTc Study to Investigate the Effects of Rovalpituzumab Tesirine on Cardiac Ventricular Repolarization in Subjects With Small Cell Lung Cancer
An Open-label, Single-Arm, Phase 2 Study Evaluating the Efficacy, Safety and Pharmacokinetics of Rovalpituzumab Tesirine (SC16LD6.5) for Third-line and Later Treatment of Subjects With Relapsed or Refractory Delta-Like Protein 3-Expressing Small Cell Lung Cancer (TRINITY)
An Open-Label Study of Rovalpituzumab Tesirine in Subjects With Delta-Like Protein 3-Expressing Advanced Solid Tumors
For information about becoming an investigator or enrolling patients in clinical trials, please submit an information request through AbbVieMedInfo.com.
Go to AbbVieMedInfo.com
Learn more about our policy regarding access to investigational drugs. Read our full statement and FAQs on our corporate website.
Go to AbbVie.com
You are about to leave for a 3rd party website
The "Yes" link below will take you out of the AbbVie family of websites.
Links which take you out of the AbbVie worldwide websites are not under the control of AbbVie, and AbbVie is not responsible for the contents of any such site or any further links from such site. AbbVie is providing these links to you only as a convenience and the inclusion of any link does not imply endorsement of the linked site by AbbVie.
The Internet site that you have requested may not be optimized to your screen size.
Do you wish to leave this site?
You are about to leave AbbVieScience.com/oncology
You are about to leave this site and be redirected to AbbVie's corporate website.
Do you wish to proceed?
The site you've requested is intended to provide information for healthcare professionals residing in the US.
I am a healthcare professional residing in the US.
I am not a healthcare professional residing in the US.